Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
None
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-

Alteplase for Acute Ischemic Stroke Within 4.5 Hours

  • 0 views
  • 05 Aug, 2021
  • 61 locations
None
Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion

allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase before undergoing intra-arterial clot retrieval. The trial is

stenosis
thrombolytic agent
plasminogen
alteplase
thrombectomy
  • 0 views
  • 01 Jul, 2021
  • 7 locations
None
REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients ( REMOTE-CAT)

Stroke is one of the leading causes of death worldwide and the main cause of incapacity. Currently, the only therapies for acute ischemic stroke (AIS) patients are the administration of recombinant tissue plasminogen activator (rt-PA) and/or endovascular treatment. Unfortunately, many patients cannot benefit from these therapies due to contraindications or …

ischemia
alteplase
stroke
arterial occlusion
plasminogen
  • 1 views
  • 23 Jan, 2021
  • 2 locations
None
Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke

A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study (respectively Part 1 and 2). The study evaluates the efficacy and safety of a fixed dose of glenzocimab (1000 mg IV over 6 hrs including initial bolus of 15 minutes) on top of the …

  • 0 views
  • 13 Oct, 2021
  • 1 location
None
  • 0 views
  • 27 Jan, 2021
  • 7 locations
None
Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke

Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV

intracranial hemorrhage
alteplase
thrombolytic agent
stroke
thrombolytic therapy
  • 1 views
  • 26 Jun, 2021
  • 1 location
None
A Phase III Randomized Blind Double Dummy Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion

The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours improve visual deficit due to acute CRAO with a good safety profile.

  • 22 views
  • 11 Nov, 2021
  • 28 locations
None
Fingolimod in Endovascular Treatment of Ischemic Stroke

outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This study aim to determine

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK)

reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset. This study intends to explore the proportion of sufficient

alteplase
plasminogen
thrombectomy
stroke
  • 0 views
  • 12 Aug, 2021
  • 1 location
None
Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke

The clinical study with UMC119-06 is designed to investigate the safety in patients with acute ischemic stroke ("AIS"). This will be a dose escalation, open-label, single-center study in adult with acute ischemic stroke. UMC119-06 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product which is intended for …

  • 1 views
  • 03 May, 2021
  • 1 location